AR020065A1 - USE OF CISTEINE PROTEASE INHIBITORS FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITION - Google Patents
USE OF CISTEINE PROTEASE INHIBITORS FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITIONInfo
- Publication number
- AR020065A1 AR020065A1 ARP990101578A ARP990101578A AR020065A1 AR 020065 A1 AR020065 A1 AR 020065A1 AR P990101578 A ARP990101578 A AR P990101578A AR P990101578 A ARP990101578 A AR P990101578A AR 020065 A1 AR020065 A1 AR 020065A1
- Authority
- AR
- Argentina
- Prior art keywords
- ylcarbonyl
- thiazol
- leucinyl
- hydrazide
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Se refiere a composicion farmacéuticas que inhiben proteasas, tales como las proteasas de cisteína. En particular, se refiere al uso de inhibidores deproteasas de cisteína para la fabricacion de un medicamento para inhibir las proteasas de cisteína,que comprende un compuesto elegido entre el grupo formadopor 2-[N-(N-benciloxicarbonilglicinil)]-2-[N-benciloxicarbonil-L-leucinil)]carbohidrazida; (3RS)-1-(N-benciloxilocarbonil-L-leucinil)-3-[N(4-fenoxibenzoil)amino]pirrolidin-4-ona; (1S)-N-[2-[1-(N-benciloxicarbonilamino)-3-metilbutil]-tiazol-4-ilcarbonil]]-N-[N-(2-piridinilmetoxicarbonil)-L-leucinil]hidrazida; 1-(N-benciloxicarbonil-L-leucinilamino)-3-(2-benciloxifenilsulfonil)amino-propan-2-ona; N-[2-(2-benciloxifenil)tiazol-4-ilcarbonil]-N-[N-(3-piridinilmetoxi-carbonil)-L-leucinil]hidrazida; (1S)-N-[2-[1-(N-benciloxicarbonilamino)-3-metilbutil]-tiazol-4-ilcarbonil-N-[N(3-piridinilmetoxicarbonil)-L-leucinil]]hidrazida; 1-[N-(4-morfolinocarbamoil)-L-leucinilamino]-3-(4-fenoxifenilsulfonil)amino-propan-2-ona; N-[2-(1-naftil)tiazol-4-ilcarbonil]-N-[N-(4-piridinil-metoxicarbonil)-L-leucinil]hidrazida; N-[2-(2-benciloxifenil)tiazol-4-ilcarbonil]-N-(N-pirazinacarbonil-L-leucinil)hidrazida; N-[N-(1-bencil-5-metilimidazol-4-ilcarbonil)-L-leucinil]-N-[2-(1-naftil)tiazol-4-ilcarbonil]hidrazida; (3RS)-3-[N-(-benciloxibenzoil)-L-leucinilamino]tetrahidrofuran-4-ona; N-[2-[N-ciclopropil-N-(2-metilpropil)amino]tiazol-4-il-carbonil]-N-[N-(5-metil-2-feniloxazol-4-ilcarbonil)-L-leucinil]hidrazida; 1-[3-(2-piridinil)fenilacetamilano]-3-[N-(2-tiofenocarbonil)-L-leucinilamino]propan-2-ona; (3S)-3-[N-(benzotiazol-6-ilcrbonil)-L-leucinilamino]-1-[3-(2-piridinil)fenilacetilamino]butan-2-ona; N-[2-[N-ciclopropil-N-(2-metilpropil)amino]tiazol-4-il-carbonil]-N-[N-(7-metoxibenzofuran-2-ilcarbonil)-L-beta-ciclopropilalanil]hidrazida; 1-[N-(benzoxazol-5-ilcarbonil)-L-leucinilamino]-3-[3-2-piridinil)fenilacetilamino]propan-2-ona; 1-[N-[4-[2-(N,N-dimetilamino)etoxi]benzoil]-L-leucinilamino]-3-[3-(2-piridinil)fenilacetilamino]propan-2-ona; y N-[2-[N-ciclopropil-N-(2-metilpropil)amino)tiazol-4-il-carbonil]-N-[N-[5[2-(N,N-dimetilamino)etoxi]benzofuran-2-ilcarbonil]-It refers to pharmaceutical compositions that inhibit proteases, such as cysteine proteases. In particular, it refers to the use of cysteine deprotease inhibitors for the manufacture of a medicament for inhibiting cysteine proteases, which comprises a compound chosen from the group consisting of 2- [N- (N-benzyloxycarbonylglycinyl)] - 2- [N -benzyloxycarbonyl-L-leucinyl)] carbohydrazide; (3RS) -1- (N-benzyloxylocarbonyl-L-leuccinyl) -3- [N (4-phenoxybenzoyl) amino] pyrrolidin-4-one; (1S) -N- [2- [1- (N-Benzyloxycarbonylamino) -3-methylbutyl] -thiazol-4-ylcarbonyl]] - N- [N- (2-pyridinylmethoxycarbonyl) -L-leucinyl] hydrazide; 1- (N-benzyloxycarbonyl-L-leuccinylamino) -3- (2-benzyloxyphenylsulfonyl) amino-propan-2-one; N- [2- (2-benzyloxyphenyl) thiazol-4-ylcarbonyl] -N- [N- (3-pyridinylmethoxycarbonyl) -L-leucinyl] hydrazide; (1S) -N- [2- [1- (N-Benzyloxycarbonylamino) -3-methylbutyl] -thiazol-4-ylcarbonyl-N- [N (3-pyridinylmethoxycarbonyl) -L-leucinyl]] hydrazide; 1- [N- (4-morpholinocarbamoyl) -L-leucinylamino] -3- (4-phenoxyphenylsulfonyl) amino-propan-2-one; N- [2- (1-Naphthyl) thiazol-4-ylcarbonyl] -N- [N- (4-pyridinyl-methoxycarbonyl) -L-leucinyl] hydrazide; N- [2- (2-benzyloxyphenyl) thiazol-4-ylcarbonyl] -N- (N-pyrazinecarbonyl-L-leucinyl) hydrazide; N- [N- (1-benzyl-5-methylimidazol-4-ylcarbonyl) -L-leucinyl] -N- [2- (1-naphthyl) thiazol-4-ylcarbonyl] hydrazide; (3RS) -3- [N - (- benzyloxybenzoyl) -L-leucinylamino] tetrahydrofuran-4-one; N- [2- [N-cyclopropyl-N- (2-methylpropyl) amino] thiazol-4-yl-carbonyl] -N- [N- (5-methyl-2-phenyloxazol-4-ylcarbonyl) -L-leucinyl ] hydrazide; 1- [3- (2-Pyridinyl) phenylacetamine] -3- [N- (2-thiophenecarbonyl) -L-leuccinylamino] propan-2-one; (3S) -3- [N- (benzothiazol-6-ylcrbonyl) -L-leucinylamino] -1- [3- (2-pyridinyl) phenylacetylamino] butan-2-one; N- [2- [N-cyclopropyl-N- (2-methylpropyl) amino] thiazol-4-yl-carbonyl] -N- [N- (7-methoxybenzofuran-2-ylcarbonyl) -L-beta-cyclopropylalanyl] hydrazide ; 1- [N- (benzoxazol-5-ylcarbonyl) -L-leucinylamino] -3- [3-2-pyridinyl) phenylacetylamino] propan-2-one; 1- [N- [4- [2- (N, N-dimethylamino) ethoxy] benzoyl] -L-leucinylamino] -3- [3- (2-pyridinyl) phenylacetylamino] propan-2-one; and N- [2- [N-cyclopropyl-N- (2-methylpropyl) amino) thiazol-4-yl-carbonyl] -N- [N- [5 [2- (N, N-dimethylamino) ethoxy] benzofuran- 2-ilcarbonyl] -
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8122198P | 1998-04-09 | 1998-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR020065A1 true AR020065A1 (en) | 2002-04-10 |
Family
ID=22162839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101578A AR020065A1 (en) | 1998-04-09 | 1999-04-07 | USE OF CISTEINE PROTEASE INHIBITORS FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITION |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1068304A4 (en) |
JP (1) | JP2002511491A (en) |
KR (1) | KR20010042535A (en) |
CN (1) | CN1304447A (en) |
AR (1) | AR020065A1 (en) |
AU (1) | AU3482099A (en) |
CA (1) | CA2327282A1 (en) |
CO (1) | CO5080800A1 (en) |
DZ (1) | DZ2752A1 (en) |
HU (1) | HUP0101513A2 (en) |
IL (1) | IL138628A0 (en) |
MA (1) | MA26618A1 (en) |
NO (1) | NO20005032L (en) |
PE (1) | PE20000421A1 (en) |
PL (1) | PL343373A1 (en) |
TR (1) | TR200002940T2 (en) |
WO (1) | WO1999053039A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143742A (en) * | 1997-12-11 | 2000-11-07 | Fuisz Technologies Ltd | Treatment for necrotizing infections |
DZ2796A1 (en) * | 1998-05-21 | 2003-12-01 | Smithkline Beecham Corp | New bis-aminomethyl-carbonyl compounds, process for their preparation and pharmaceutical compositions containing them. |
US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
EP1143951A3 (en) | 1998-09-21 | 2002-02-06 | University Of Florida Research Foundation, Inc. | Antimalarial agents |
EP1488791A3 (en) * | 1998-09-21 | 2005-04-06 | University Of Florida Research Foundation, Inc. | Antimalarial agents |
CO5150165A1 (en) * | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | PROTEASE INHIBITORS: KATEPSIN K TYPE |
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034599A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
US6583137B1 (en) | 1999-11-10 | 2003-06-24 | Smithkline Beecham Corporation | Protease inhibitors |
JP2003513924A (en) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
CN1416346A (en) | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | Peotease inhibitors |
US6635784B2 (en) | 2000-09-29 | 2003-10-21 | Eastman Chemical Company | Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates |
ES2261341T3 (en) * | 2000-11-17 | 2006-11-16 | Medivir Ab | CISTEINE PROTEASA INHIBITOR. |
MXPA03006224A (en) | 2001-01-17 | 2004-10-15 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases. |
US7132449B2 (en) | 2001-01-17 | 2006-11-07 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
IL156776A0 (en) | 2001-01-17 | 2004-02-08 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases |
EP1465862A1 (en) | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
WO2005034949A1 (en) | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
TR201910900T4 (en) | 2005-04-04 | 2019-08-21 | Univ Florida | Desferritiokine polyether analogs. |
WO2007012180A1 (en) * | 2005-07-26 | 2007-02-01 | Merck Frosst Canada Ltd. | Papain family cysteine protease inhibitors for the treatment of parasitic diseases |
NZ579994A (en) | 2007-03-15 | 2011-09-30 | Univ Florida | Desferrithiocin polyether analogues useful in the treatment of pathological conditions responsive to chelation or sequestration of trivalent metal |
EP2225196B1 (en) | 2007-11-29 | 2015-01-28 | Merck Canada Inc. | Cysteine protease inhibitors for the treatment of parasitic diseases |
WO2009087379A2 (en) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases |
MX368275B (en) | 2011-12-16 | 2019-09-26 | Univ Florida | Uses of 4'-desferrithiocin analogs. |
EP2633855A1 (en) | 2012-03-01 | 2013-09-04 | Veterinärmedizinische Universität Wien | Protease inhibitors for treating Trichomonas gallinae infections |
JP6838966B2 (en) | 2013-11-22 | 2021-03-03 | ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. | Desfericiosin analogs and their use |
KR20170140306A (en) | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Metabolically programmed metal chelating agents and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
CZ132798A3 (en) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Protease inhibitors |
DZ2285A1 (en) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Cysteine protease inhibitors. |
MA26487A1 (en) * | 1997-04-29 | 2004-12-20 | Smithkline Beecham Corp | PROTEASE INHIBITOR HETEROCYCLECETOHYDRAZIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
-
1999
- 1999-04-05 MA MA25522A patent/MA26618A1/en unknown
- 1999-04-07 AR ARP990101578A patent/AR020065A1/en unknown
- 1999-04-07 DZ DZ990053A patent/DZ2752A1/en active
- 1999-04-08 CO CO99020595A patent/CO5080800A1/en unknown
- 1999-04-08 PL PL99343373A patent/PL343373A1/en not_active Application Discontinuation
- 1999-04-08 WO PCT/US1999/007723 patent/WO1999053039A1/en not_active Application Discontinuation
- 1999-04-08 EP EP99916517A patent/EP1068304A4/en not_active Withdrawn
- 1999-04-08 HU HU0101513A patent/HUP0101513A2/en unknown
- 1999-04-08 CN CN99807012A patent/CN1304447A/en active Pending
- 1999-04-08 IL IL13862899A patent/IL138628A0/en unknown
- 1999-04-08 TR TR2000/02940T patent/TR200002940T2/en unknown
- 1999-04-08 KR KR1020007011178A patent/KR20010042535A/en not_active Application Discontinuation
- 1999-04-08 CA CA002327282A patent/CA2327282A1/en not_active Abandoned
- 1999-04-08 AU AU34820/99A patent/AU3482099A/en not_active Abandoned
- 1999-04-08 JP JP2000543587A patent/JP2002511491A/en not_active Withdrawn
- 1999-04-09 PE PE1999000290A patent/PE20000421A1/en not_active Application Discontinuation
-
2000
- 2000-10-06 NO NO20005032A patent/NO20005032L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2327282A1 (en) | 1999-10-21 |
NO20005032D0 (en) | 2000-10-06 |
EP1068304A1 (en) | 2001-01-17 |
IL138628A0 (en) | 2001-10-31 |
JP2002511491A (en) | 2002-04-16 |
CO5080800A1 (en) | 2001-09-25 |
MA26618A1 (en) | 2004-12-20 |
HUP0101513A2 (en) | 2001-08-28 |
NO20005032L (en) | 2000-11-16 |
EP1068304A4 (en) | 2001-05-09 |
PL343373A1 (en) | 2001-08-13 |
AU3482099A (en) | 1999-11-01 |
CN1304447A (en) | 2001-07-18 |
TR200002940T2 (en) | 2001-02-21 |
DZ2752A1 (en) | 2003-09-15 |
PE20000421A1 (en) | 2000-05-21 |
KR20010042535A (en) | 2001-05-25 |
WO1999053039A1 (en) | 1999-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR020065A1 (en) | USE OF CISTEINE PROTEASE INHIBITORS FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITION | |
RU2368604C2 (en) | Phosphodiestarase 4 inhibitors, containing n-substituted aniline and diphenylamine analogues | |
EA200200975A1 (en) | HYDROCHLORIDE 5- [4- [2- (N-METHYL-N- (2-Pyridyl) AMINO) ETOXY] BENZYL] THIAZOLIDIN-2,4-DIONA | |
AR054445A1 (en) | FORMULATIONS OF AN SRC / ABL INHIBITOR | |
RS51343B (en) | Novel composition and use | |
AR051965A1 (en) | SALTS OF THE N- [2- ({(3R) -1- [TRANS-4-HIDROXI-4- (6- METOXIPIRIDIN-3-IL) -CICLOHEXIL] PIRROLIDIN-3- IL} AMINO) -2- OXOETIL] -3- (TRIFLUORMETIL) BENZAMIDA | |
EA200702238A1 (en) | COMBINATION, METHOD AND COMPOSITION FOR CANCER TREATMENT | |
YU7998A (en) | Heterocyclic compounds and their pharmaceutic compositions | |
DE69816280D1 (en) | INHIBITORS OF THE IMPDH ENZYME | |
PE20071184A1 (en) | AMINOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF LUPUS CUTANEO | |
MY106315A (en) | Pharmaceutical agents | |
NO20091892L (en) | Crystalline form of (3S) -3- (N- (N'- (2-tert-butylphenyl) oxamyl) alaninyl) amino-5- (2`, 3`, 5`, 6'-tetrafluorophenoxy) -4-oxopentanoic acid | |
MX2023012521A (en) | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino )-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroet hyl)pyrrolidine-1-carboxamide and salts thereof. | |
EA200400253A1 (en) | APPLICATION OF BIBN4096BS COMPOUND IN COMBINATION WITH OTHER MEDICINAL AGENTS AGAINST MIGRAINE FOR THE TREATMENT OF MIGRAIN | |
AR014270A1 (en) | INHIBITORY SUBSTANCE OF MATRIX METALOPROTEASES, PHARMACEUTICAL COMPOSITION, USE IN THE MANUFACTURE OF MEDICINES, PROCEDURE FOR MANUFACTURING AND INTERMEDIATE COMPOUNDS | |
PE20050440A1 (en) | N-HETEROCYCLE DERIVATIVES SUBSTITUTED TO MODIFY MONOAMINE RECAPTATION | |
WO2006114702A3 (en) | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor | |
DE60103284D1 (en) | ANTIFUNGICIDE COMPOSITION OF KETOCONAZOLE FOR APPLICATION | |
HUP0300938A2 (en) | The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
TW200501956A (en) | Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine | |
NO20042871L (en) | Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof | |
HUP0001591A2 (en) | Fungicidal composition containing metalaxyl and dimetomorph and use thereof | |
RU2003116893A (en) | NEW APPLICATION OF THE UNITED 5-NT1A AGONISTS AND SEROTONIN REVERSION INHIBITORS | |
ATE141248T1 (en) | NEW BIS-PHENYL WITCHES | |
Kim et al. | (4-Piperidinylphenyl) aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors |